🏛️ Verified NIH Record • Updated 2026-08-20
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies (NCT06634589)
🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: BeOne Medicines
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Phoenix — Phoenix, Arizona
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (50 Sites)
- Mayo Clinic Phoenix — Phoenix, Arizona
- University of Southern California Norris Comprehensive — Los Angeles, California
- Mayo Clinic Jacksonville — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
- The University of Kansas Cancer Center — Westwood, Kansas
- Mayo Clinic Rochester — Rochester, Minnesota
- Washington University School of Medicine — St Louis, Missouri
- Summit Medical Group — Florham Park, New Jersey
- Icahn School of Medicine At Mount Sinai — New York, New York
- Columbia University Medical Center — New York, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital — New York, New York
- Memorial Sloan Kettering Cancer Center Mskcc — New York, New York
- University of Rochester — Rochester, New York
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- The University of Texas Md Anderson Cancer Center — Houston, Texas
- Huntsman Cancer Institute — Salt Lake City, Utah
- University of Wisconsin — Madison, Wisconsin
- Medical College of Wisconsin — Milwaukee, Wisconsin
- St George Hospital — Kogarah, New South Wales
- Mater Cancer Care Centre — South Brisbane, Queensland
- Monash Health — Clayton, Victoria
- Peter Maccallum Cancer Centre — Melbourne, Victoria
- The Alfred Hospital — Melbourne, Victoria
- Linear Clinical Research — Nedlands, Western Australia
- Hospital Sirio Libanes Brasilia — Brasília,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.